GLI2 Orchestrates Tumor Immune Evasion via WNT and Prostaglandin Pathways

Study Background and Research Question

Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet durable responses remain limited by both primary and acquired resistance mechanisms. A growing body of evidence implicates tumor mesenchymal transformation (MT)—a process driven by factors such as TGFβ and hypoxia—in fostering immune evasion and therapeutic failure. However, the precise molecular orchestrators linking MT to a suppressive tumor microenvironment (TME) and immunotherapy resistance have remained elusive. The reference study by DeVito et al. (summary) addresses this gap by investigating whether the Hedgehog pathway transcription factor GLI2 acts as a central node that coordinates immune evasion in tumors undergoing MT, and whether targeting GLI2-regulated pathways could reverse immunosuppressive features and improve immunotherapeutic efficacy.

Key Innovation from the Reference Study

The core innovation of this research lies in identifying GLI2 as a master regulator that links mesenchymal transformation to immune suppression and resistance to anti-PD-1 therapy. The authors demonstrate that during MT, GLI2 upregulates both WNT ligand secretion and prostaglandin biosynthesis, which collectively shape an immunotolerant TME. Notably, GLI2-driven signaling recruits granulocytic myeloid-derived suppressor cells (PMN-MDSCs) and impairs the function of key antitumor effectors, including type I conventional dendritic cells, CD8⁺ T cells, and natural killer (NK) cells. Pharmacologic or genetic blockade of GLI2-coordinated pathways restores immune cell function and sensitizes tumors to ICB. The study also correlates a GLI2 transcriptional signature with clinical resistance to anti-PD-1 therapy in stage IV melanoma patients, providing translational relevance.

Methods and Experimental Design Insights

To dissect the mechanistic role of GLI2, DeVito et al. employed a multi-tiered experimental strategy:

• Genetic and pharmacologic manipulation of GLI2 in murine melanoma and lung cancer models, including the use of GLI2 overexpression and knockdown constructs.
• Assessment of mesenchymal traits, WNT ligand (notably WNT5a) expression, and prostaglandin biosynthesis in GLI2-modulated cells and tumors.
• Flow cytometric and functional analyses of TME immune cell composition, focusing on PMN-MDSC recruitment and the status of dendritic, CD8⁺, and NK cells.
• Tumor response studies using anti-PD-1 therapy, with or without inhibitors targeting WNT secretion or prostaglandin E2 (PGE2) receptor (EP2/EP4) signaling.
• Transcriptional profiling and pathway analysis to define GLI2 target gene signatures in both murine and human tumor samples.
• Correlation of the GLI2 signature with clinical datasets from melanoma patients treated with ICB.

This integrative approach allowed the authors to map causal links from GLI2 activity to downstream immunomodulatory effects and therapy outcomes.

Core Findings and Why They Matter

Key findings from the study include:

• GLI2 upregulation during mesenchymal transformation: Tumors exhibiting MT display increased GLI2 activity, which in turn drives the production of WNT ligands and prostaglandins.
• Promotion of immunosuppression: Through its dual influence, GLI2 fosters the recruitment and functional maintenance of PMN-MDSCs, cells known to suppress antitumor immunity and facilitate metastasis. This is accompanied by impaired dendritic cell activation, reduced cytotoxic T lymphocyte (CTL) infiltration and activity, and diminished NK cell function.
• Therapeutic resistance: Tumors with high GLI2 activity are resistant to anti-PD-1 checkpoint therapy. Importantly, pharmacologic inhibition of either WNT secretion or EP2/EP4 signaling can reverse discrete aspects of the suppressive TME and restore responsiveness to immunotherapy (see summary).
• Clinical correlation: A GLI2-driven gene expression signature is associated with poor response to anti-PD-1 therapy in human melanoma, underscoring the translational significance of these mechanistic insights.

Collectively, these data establish GLI2 as a druggable hub integrating oncogenic signaling, mesenchymal plasticity, and immune escape, and suggest that GLI2 inhibition could be leveraged to enhance the efficacy of immunotherapies across tumor types.

Comparison with Existing Internal Articles

Recent internal articles reinforce and expand upon the mechanistic and translational observations of the DeVito et al. study. For example, "GANT61: Selective GLI Inhibitor Workflow for Tumor Research" and "GANT61: Precision GLI Inhibitor Workflows in Cancer Research" detail how the selective GLI inhibitor GANT61 can be used to dissect GLI-mediated transcription inhibition and overcome immunotherapy resistance, particularly in neuroblastoma and rhabdomyosarcoma models. These resources provide protocol guidance for integrating GLI inhibition into advanced cancer research workflows and troubleshooting strategies for maximizing impact. In addition, the internal article "GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin Pathways" offers an accessible summary of the reference paper’s mechanistic framework, highlighting the interconnectedness of the Hedgehog, WNT, and prostaglandin pathways in immune regulation. Collectively, these articles support the translational value of targeting GLI2 in various tumor settings and provide practical insights into experimental design.

Limitations and Transferability

While the reference study provides compelling preclinical evidence for GLI2 as a central driver of immune evasion and therapy resistance, several limitations should be considered:

• Most experimental findings are derived from murine models of melanoma and lung cancer; extrapolation to additional tumor types or human in vivo settings requires further validation.
• Although the study demonstrates reversal of immunosuppression by targeting WNT or prostaglandin signaling downstream of GLI2, direct GLI2 inhibition was not tested in clinical models or patient samples.
• The complexity of TME interactions means that compensatory immune escape pathways may emerge with single-pathway targeting.

Nevertheless, the mechanistic clarity and clinical correlation provided by the GLI2 transcriptional signature analysis support the relevance of these pathways to human cancer immunotherapy. For researchers, careful consideration of tumor context and combinatorial strategies will be essential when translating these insights to the clinic.

Protocol Parameters

• GLI2 pathway modulation: Use genetic knockdown, overexpression, or selective GLI inhibitors to interrogate the role of GLI2 in immune evasion models.
• WNT/prostaglandin pathway inhibition: Apply pharmacologic inhibitors of WNT secretion (e.g., porcupine inhibitors) or EP2/EP4 antagonists to dissect downstream effects on the TME.
• Immune cell profiling: Employ multiparameter flow cytometry and functional assays to quantify PMN-MDSCs, dendritic cell, CD8⁺ T cell, and NK cell populations following pathway modulation.
• ICB response assessment: Combine pathway inhibitors with anti-PD-1 therapy in preclinical tumor models to evaluate changes in therapeutic sensitivity.
• GLI transcriptional signature analysis: Utilize gene expression profiling to stratify tumors or patient samples based on GLI2 activity for correlative studies.

Research Support Resources

For researchers interested in targeting GLI-mediated transcription inhibition or modeling Hedgehog pathway-driven tumor immune evasion, the selective GLI antagonist GANT61 (SKU A1615) is available from APExBIO. GANT61 inhibits GLI1/2 transcriptional activity and is widely used in advanced cancer research to dissect the mechanistic basis of tumor growth suppression and immune resistance, including in neuroblastoma and other GLI-driven models. Practical details regarding dosing, solubility, and workflow integration can be found in the internal workflow guide and the product information page. Employing GANT61 in combination with immune profiling and pathway inhibition strategies will enable further exploration of GLI2’s role in tumor immunology and therapy resistance.